Patrick Ott, MD, PhD
In this video series, Patrick Ott, MD, PhD, director of clinical sciences at the Center for Immuno-Oncology Clinical, director of the Melanoma Disease Center and senior physician at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, talked about:
- the potential of personalized vaccines that can target mutations “that are present in every tumor;”
- tumor-agnostic therapies for NTRK mutations and PD-1 inhibition;
- why education about these drugs “applies to community oncologists just as much as it applies to a more specialized academic oncologist;”
- his uncertainty about “how broadly these agents will be used in oncology;”
- considerations for future research;
- ongoing trials on using personalized vaccines in the melanoma space; and
- the differences between potentially identifying patients for personalized vaccines that target mutations vs. identifying patients for other tumor-agnostic therapies.